Cetuximab (English Wikipedia)

Nguyen A, Hoang V, Laquer V, Kelly KM (December 2009). "Angiogenesis in cutaneous disease: part I". Journal of the American Academy of Dermatology. 61 (6): 921–42, quiz 943–4. doi:10.1016/j.jaad.2009.05.052. PMID 19925924. S2CID 2618247.

espacenet.com

worldwide.espacenet.com

US patent 6217866, Sela M, Pirak E, Hurwitz E, "Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same", published 2001-04-17, assigned to Yeda Research & Development

europa.eu

ema.europa.eu

"Erbitux EPAR". European Medicines Agency. 17 September 2018. Retrieved 2 June 2022.

fda.gov

"Class Labeling Changes to anti-EGFR monoclonal antibodies, cetuximab (Erbitux) and panitumumab (Vectibix): KRAS Mutations". U.S. Food and Drug Administration (FDA). 2010-01-11.
"Therascreen KRAS RGQ PCR Kit – P110030". Device Approvals and Clearances. U.S. Food and Drug Administration (FDA). 2012-07-06.
Research, Center for Drug Evaluation and (2024-06-21). "FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer". FDA.

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.

fiercepharma.com

Top 10 best-selling cancer drugs of 2013; May 29, 2014

gabionline.net

Generics and Biosimilars Initiative (GaBI) – Biosimilars of cetuximab – 14/08/2014

harvard.edu

ui.adsabs.harvard.edu

Rabara D, Tran TH, Dharmaiah S, Stephens RM, McCormick F, Simanshu DK, Holderfield M (October 2019). "KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis". Proceedings of the National Academy of Sciences of the United States of America. 116 (44): 22122–22131. Bibcode:2019PNAS..11622122R. doi:10.1073/pnas.1908353116. PMC 6825300. PMID 31611389.

legalmetric.com

"Yeda Research v. Imclone Systems, et al". Archived from the original on 2015-11-20. Retrieved 2015-08-30.

lilly.com

investor.lilly.com

Eli Lilly and Company Form 10-K Annual Report 2013

merckgroup.com

Merck Serono Investor & Analyst Day 2014 – Belen Garijo's presentation – Slide 41. 18 Sept 2014

mskcc.org

Grisham, Julie (2024-06-21). "FDA Approves First Colorectal Cancer Treatment that Targets KRAS Gene | Memorial Sloan Kettering Cancer Center". www.mskcc.org. Retrieved 2024-07-19.

nih.gov

pubmed.ncbi.nlm.nih.gov

Messersmith WA, Ahnen DJ (October 2008). "Targeting EGFR in colorectal cancer". The New England Journal of Medicine. 359 (17): 1834–1836. doi:10.1056/NEJMe0806778. PMID 18946069.
Rosenthal DI, Harari PM, Giralt J, Bell D, Raben D, Liu J, et al. (April 2016). "Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab". Journal of Clinical Oncology. 34 (12): 1300–1308. doi:10.1200/JCO.2015.62.5970. PMC 5070577. PMID 26712222.
Jeong IS, Mo H, Nguyen A, Chong EG, Tsai HH, Moyers J, et al. (2020). "Primary chemoradiation with cisplatin versus cetuximab for locally advanced head and neck cancer: a retrospective cohort study". Experimental Hematology & Oncology. 9: 19. doi:10.1186/s40164-020-00175-1. PMC 7409407. PMID 32775042.
Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. (January 2019). "Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial". Lancet. 393 (10166): 40–50. doi:10.1016/S0140-6736(18)32779-X. PMC 6541928. PMID 30449625.
Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. (January 2019). "Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial". Lancet. 393 (10166): 51–60. doi:10.1016/S0140-6736(18)32752-1. PMC 6319250. PMID 30449623.
Nguyen A, Hoang V, Laquer V, Kelly KM (December 2009). "Angiogenesis in cutaneous disease: part I". Journal of the American Academy of Dermatology. 61 (6): 921–42, quiz 943–4. doi:10.1016/j.jaad.2009.05.052. PMID 19925924. S2CID 2618247.
Berg EA, Platts-Mills TA, Commins SP (February 2014). "Drug allergens and food--the cetuximab and galactose-α-1,3-galactose story". Annals of Allergy, Asthma & Immunology. 112 (2): 97–101. doi:10.1016/j.anai.2013.11.014. PMC 3964477. PMID 24468247.
Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. (March 2008). "Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose". The New England Journal of Medicine. 358 (11): 1109–1117. doi:10.1056/NEJMoa074943. PMC 2361129. PMID 18337601.
Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. (April 2009). "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer". The New England Journal of Medicine. 360 (14): 1408–1417. doi:10.1056/NEJMoa0805019. PMID 19339720.
Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, et al. (July 2012). "Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials". European Journal of Cancer. 48 (10): 1466–1475. doi:10.1016/j.ejca.2012.02.057. PMID 22446022.
De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. (October 2010). "Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab". JAMA. 304 (16): 1812–1820. doi:10.1001/jama.2010.1535. PMID 20978259.
McFall T, Diedrich JK, Mengistu M, Littlechild SL, Paskvan KV, Sisk-Hackworth L, et al. (September 2019). "A systems mechanism for KRAS mutant allele-specific responses to targeted therapy". Science Signaling. 12 (600): 8288. doi:10.1126/scisignal.aaw8288. PMC 6864030. PMID 31551296.
Rabara D, Tran TH, Dharmaiah S, Stephens RM, McCormick F, Simanshu DK, Holderfield M (October 2019). "KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis". Proceedings of the National Academy of Sciences of the United States of America. 116 (44): 22122–22131. Bibcode:2019PNAS..11622122R. doi:10.1073/pnas.1908353116. PMC 6825300. PMID 31611389.
Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M (December 1988). "Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice". Journal of the National Cancer Institute. 80 (20): 1605–1611. doi:10.1093/jnci/80.20.1605. PMID 3193478.
Schrag D (July 2004). "The price tag on progress--chemotherapy for colorectal cancer". The New England Journal of Medicine. 351 (4): 317–319. doi:10.1056/NEJMp048143. PMID 15269308.
Li K, Li J (2016). "Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application". Gastroenterology Research and Practice. 2016: 4105615. doi:10.1155/2016/4105615. PMC 4736909. PMID 26880889.
Bridgewater JA, Pugh SA, Maishman T, Eminton Z, Mellor J, Whitehead A, et al. (March 2020). "Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial". The Lancet. Oncology. 21 (3): 398–411. doi:10.1016/S1470-2045(19)30798-3. PMC 7052737. PMID 32014119.

ncbi.nlm.nih.gov

Rosenthal DI, Harari PM, Giralt J, Bell D, Raben D, Liu J, et al. (April 2016). "Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab". Journal of Clinical Oncology. 34 (12): 1300–1308. doi:10.1200/JCO.2015.62.5970. PMC 5070577. PMID 26712222.
Jeong IS, Mo H, Nguyen A, Chong EG, Tsai HH, Moyers J, et al. (2020). "Primary chemoradiation with cisplatin versus cetuximab for locally advanced head and neck cancer: a retrospective cohort study". Experimental Hematology & Oncology. 9: 19. doi:10.1186/s40164-020-00175-1. PMC 7409407. PMID 32775042.
Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. (January 2019). "Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial". Lancet. 393 (10166): 40–50. doi:10.1016/S0140-6736(18)32779-X. PMC 6541928. PMID 30449625.
Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. (January 2019). "Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial". Lancet. 393 (10166): 51–60. doi:10.1016/S0140-6736(18)32752-1. PMC 6319250. PMID 30449623.
Berg EA, Platts-Mills TA, Commins SP (February 2014). "Drug allergens and food--the cetuximab and galactose-α-1,3-galactose story". Annals of Allergy, Asthma & Immunology. 112 (2): 97–101. doi:10.1016/j.anai.2013.11.014. PMC 3964477. PMID 24468247.
Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. (March 2008). "Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose". The New England Journal of Medicine. 358 (11): 1109–1117. doi:10.1056/NEJMoa074943. PMC 2361129. PMID 18337601.
McFall T, Diedrich JK, Mengistu M, Littlechild SL, Paskvan KV, Sisk-Hackworth L, et al. (September 2019). "A systems mechanism for KRAS mutant allele-specific responses to targeted therapy". Science Signaling. 12 (600): 8288. doi:10.1126/scisignal.aaw8288. PMC 6864030. PMID 31551296.
Rabara D, Tran TH, Dharmaiah S, Stephens RM, McCormick F, Simanshu DK, Holderfield M (October 2019). "KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis". Proceedings of the National Academy of Sciences of the United States of America. 116 (44): 22122–22131. Bibcode:2019PNAS..11622122R. doi:10.1073/pnas.1908353116. PMC 6825300. PMID 31611389.
Li K, Li J (2016). "Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application". Gastroenterology Research and Practice. 2016: 4105615. doi:10.1155/2016/4105615. PMC 4736909. PMID 26880889.
Bridgewater JA, Pugh SA, Maishman T, Eminton Z, Mellor J, Whitehead A, et al. (March 2020). "Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial". The Lancet. Oncology. 21 (3): 398–411. doi:10.1016/S1470-2045(19)30798-3. PMC 7052737. PMID 32014119.

dailymed.nlm.nih.gov

"Erbitux- cetuximab solution". DailyMed. 27 September 2021. Retrieved 2 June 2022.

nypost.com

Bennett C (19 August 2008). "'HALF' LIFE OF MARTHA CONVICT". New York Post. Retrieved 2 June 2022.

nytimes.com

"MARTHA STEWART'S SENTENCE: THE OVERVIEW; 5 Months in Jail, and Stewart Vows, 'I'll Be Back'". The New York Times. 17 July 2004. Retrieved 2 June 2022.

reuters.com

in.reuters.com

"Merck KGaA's Erbitux beats Avastin in bowel cancer trial, Reuters, Jun 1 2013". Archived from the original on 2016-03-06. Retrieved 2021-07-06.

semanticscholar.org

api.semanticscholar.org

Nguyen A, Hoang V, Laquer V, Kelly KM (December 2009). "Angiogenesis in cutaneous disease: part I". Journal of the American Academy of Dermatology. 61 (6): 921–42, quiz 943–4. doi:10.1016/j.jaad.2009.05.052. PMID 19925924. S2CID 2618247.

usatoday.com

"ImClone goes up against patent dispute". USA Today. 2006-09-14.

uscourts.gov

nysd.uscourts.gov

"Court ruling on Yeda vs Aventis/Imclone case" (PDF). Archived from the original (PDF) on 2011-09-27. Retrieved 2012-05-25.

web.archive.org

"Cetuximab Beneficial in Head and Neck Cancer". Cancer.gov National Cancer Institute. Archived from the original on 2010-12-21. Retrieved 2013-04-13.
"Yeda Research and Development Company Ltd". Archived from the original on 2016-12-04. Retrieved 2013-01-05. Technology Transfer Company of the Weizmann Institute of Science
Groombridge N, Gearing BP (February 2008). "Practical lessons from a "made for TV" patent litigation: The trial of Yeda Research & Development Co. Ltd. v. ImClone Systems Inc. and Aventis Pharmaceuticals Inc" (PDF). The Federal Lawyer: 51–55. Archived from the original (PDF) on 2009-09-03.
"Court ruling on Yeda vs Aventis/Imclone case" (PDF). Archived from the original (PDF) on 2011-09-27. Retrieved 2012-05-25.
"Yeda Research v. Imclone Systems, et al". Archived from the original on 2015-11-20. Retrieved 2015-08-30.
"Merck KGaA's Erbitux beats Avastin in bowel cancer trial, Reuters, Jun 1 2013". Archived from the original on 2016-03-06. Retrieved 2021-07-06.

yedarnd.com

"Yeda Research and Development Company Ltd". Archived from the original on 2016-12-04. Retrieved 2013-01-05. Technology Transfer Company of the Weizmann Institute of Science
Groombridge N, Gearing BP (February 2008). "Practical lessons from a "made for TV" patent litigation: The trial of Yeda Research & Development Co. Ltd. v. ImClone Systems Inc. and Aventis Pharmaceuticals Inc" (PDF). The Federal Lawyer: 51–55. Archived from the original (PDF) on 2009-09-03.